HSK38008 / Haisco - LARVOL DELTA

HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer (AACR 2023) - "The androgen deprivation therapy (ADT) alone and its combination with hormone therapy that block AR signaling (e.g., enzalutamide or abiraterone) are effective treatments for advanced prostate cancer. No animal was found dead or moribund and no test article-related changes in clinical signs,body weights, food consumption, ophthalmologic examinations, clinical pathology parameters, sperm analysis, urinalysis, organ weights, histopathology. In conclusion, HSK38008 is a promising oral AR-V7 degrader with better efficacy than enzalutamide and ARV-110 in AR and AR-V7 positive, and potential AR mutants mCRPC."

Late-breaking abstract • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

Haisco (002653.SZ): The oral preparation of HSK38008 has been approved to carry out clinical trials for the treatment of "prostate cancer" [Google translation] (Sina Corp) - "Haisike (002653.SZ) announced that the company has recently obtained the 'Notice of Approval for Drug Clinical Trials' issued by the Center for Drug Evaluation of the State Drug Administration, and the name of the drug is HSK38008. According to the 'Drug Administration Law of the People's Republic of China' and relevant regulations, after review, the oral preparation of HSK38008 meets the relevant requirements for drug registration, and the clinical trial of this product for the treatment of 'prostate cancer' is approved."

New trial • Genito-urinary Cancer • Oncology • Prostate Cancer